Latest Eikon Therapeutics News & Updates

See the latest news and media coverage for Eikon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Eikon Therapeutics (Eikon)

Late-stage clinical biopharmaceutical company

eikontx.com

Headquarters: Millbrae, United States
Founded year: 2019
Company type: Private company
Number of employees: 400–500

Last updated Today

Latest news about Eikon Therapeutics (Eikon)

In short: Eikon successfully completed a $381 million IPO, advanced its oncology pipeline through clinical trials, and expanded its board of directors.

Company announcements

June 8 Eikon

Eikon appoints Ma. Fatima D. Francisco to its board

Francisco, former P&G CEO, brings leadership experience to the biopharma company's board, effective June 15, 2026.

May 31 Eikon

Eikon to present Phase 2/3 study of EIK1001 combination therapy

The TeLuRide-008 trial will be presented as a poster at ASCO 2026.

May 30 Eikon

Eikon announces Phase 1/2 study of EIK1005 at ASCO 2026

The study evaluates EIK1005 as monotherapy and with pembrolizumab in advanced solid tumors, including MSI-H/dMMR.

May 30 Eikon

Eikon Therapeutics presents clinical data at ASCO 2026

Updated data for EIK1001 in NSCLC shows 63.1% ORR and 90.8% DCR, and EIK1003 shows activity in solid tumors.

Media coverage

June 2 The Globe and Mail

Eikon Highlights Promising New Clinical Data in Oncology

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Eikon Therapeutics, Inc. ( (EIKN)) has shared an update. On May...

May 30 The Globe and Mail

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated...

May 25 Newser

Eikon Therapeutics Inc. (EIKN) Slips 2.24% as Stock Holds Above Key Support...

Eikon (EIKN) stock is a buy now based on analysis covering price action trends, analyst upgrades, revenue expansion and long-term growth potential. Eikon Therapeutics Inc...

May 23 Newser

EIKN Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Stage

High Yield- Join thousands of investors using our free investing platform for market updates, portfolio recommendations, and strategic stock opportunities. Eikon Therapeutics Inc. (EIKN) reported...

Never miss news about Eikon

Track Eikon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Eikon competitors & trending companies

Browse news for competitors to Eikon and other trending companies.